-
Anna Törner: The clinical trial – Periscope to reality
What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.
-
Study: Vaccination linked to lower risk of post-COVID
The risk of developing post-COVID after a COVID infection was reduced in vaccinated people, according to a new study from the University of Gothenburg.
-
Studie: Vaccination kopplad till lägre risk för postcovid
Risken att drabbas av postcovid efter en covidinfektion minskade hos personer som vaccinerat sig, enligt en ny studie från Göteborgs universitet.
-
Cantargia tar in miljonbelopp – ”Det är väldigt positivt”
Lundabaserade Cantargia tar in 59 miljoner kronor genom en riktad nyemission. Kapitalet kommer bland annat användas till den fortsatta utvecklingen av bolagets cancerläkemedel nadunolimab.
-
Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”
It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic have achieved just that, and they are thus making a significant contribution to the history of Swedish medicine. He is now being awarded the Research!Sweden Award 2023.
-
Study names with an attitude – more important than you might think
Ironman, T-rex, Star-Trek. Popcorn, Proper, Scout. Nope, these are neither fantasy films nor dog names. They’re the names of ongoing cancer studies in Sweden.
-
Studienamn med attityd – viktigare än man kan tro
Ironman, T-rex, Star-trec. Popcorn, Proper, Scout. Nej, det handlar varken om fantasyfilmer eller hundnamn. Utan om benämningar på pågående cancerstudier i Sverige.
-
Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients
In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.
-
Samuel Lagercrantz: The government’s performance in healthcare and life sciences so far
Since the change of government in Sweden, developments in the healthcare sector have shown promising signs, but the outlook in life sciences is less promising, writes Samuel Lagercrantz in an editorial.
-
Stor kartläggning av svensk läkemedelsutveckling - "Väldigt imponerande bidrag"
Trots tuffa tider planerar två av tre life science-bolag att nyrekrytera – och antalet läkemedelsprojekt fortsätter att öka. Det visar branschorganisationen Sweden Bios stora kartläggning av svensk läkemedelsutveckling.
-
Column: ”Authentic leadership and clear mandates pave the way for more female CEOs”
”I believe that the aspect of having clear mandates and titles on the one hand and women progressing into top positions must be explored further”, Helena Strigård writes in a column.
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Redan prenumerant? Logga in
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
BREAKING